Heidi A. Dare

Shareholder

outside the office back to the office
Heidi A. Dare
Shareholder
Overview
Heidi counsels clients in patent related matters including international patent portfolio management and due diligence analyses. Heidi’s practice focuses on patent prosecution in technical areas of molecular biology, medical device and medical diagnostics. Heidi’s prosecution experience includes preparing and prosecuting applications in technologies including RNA interference, recombinant nucleic acid and protein technologies, mutational analysis, antibody therapies, transgenic animals and plants, therapeutic vectors, stem cell therapies, and gene therapy. 

Heidi counsels a diverse group of clients from corporate clients of all sizes, university clients and start-ups. Heidi has prosecuted over 1000 patent applications in the U.S. and worldwide.

Prior to joining the firm in 2002, Heidi’s non-legal experience included research positions at Howard Hughes Medical Institute, University of Michigan and the Ohio State University.

Practice Groups
Education
  • J.D.,
    Wayne State University Law School, 2002
  • M.S., Microbiology & Immunology,
    University of Michigan, 1988
  • B.A., Biology,
    Albion College, 1985
Bar Admissions
  • Illinois
  • U.S. Patent & Trademark Office
Area of Focus
Technical Background
  • Biopharma
Experience | Legal

Brinks Gilson & Lione, Chicago, Illinois
Shareholder, January 2011-Present
Associate, September 2002-December 2010 

Brooks & Kushman, P.C., Southfield, Michigan
Law Clerk, May 2001-April 2002
Supported ongoing patent prosecution and litigation, including provisional applications and trademark litigation

University of Michigan, Office of the General Counsel, Ann Arbor, Michigan
Law Clerk, 2000-2001
Researched issues for all areas of law, including patent law, copyrights, contracts, UCITA, Title IX, civil rights and property

Forward Thinking
Federal Circuit Rules That Foreign Defendants Cannot Rely On 28 U.S.C. § 1400(b) To Challenge Venue
May 14, 2018
Update on CRISPR Patent Battle
January 10, 2017
A Closer Look at Ariosa After Fed. Circ. Denies Rehearing
December 11, 2015
Versata v. SAP: The Federal Circuit Can Review the CBM-Specific Threshold Question of Whether a Patent Qualifies as a "Covered Business Method Patent"
July 17, 2015
Patent Term Extension Under 35 U.S.C. §156
March 03, 2015
"mLin-7 is Localized to the Basolateral Surface of Renal Epithelia Via its Aminoterminus," co-author with Straight, S., Karnak, D., Borg, J.P., Kamberov, E., Margolis, B. and Wade, J., Am J Physiol Renal Physiol., 278(3), March 2000, pp F464-75
March 2000
"Endotoxin-stimulated monocytes release multiple forms of IL-1 beta, including a proIL-1 beta form whose detection is affected by export," co-author with Wewers, M.D.and Winnard, A.V., J Immunol., 162(8), April 15, 1999, pp 4858-63
April 15, 1999
"Asterriquinones produced by Aspergillus candidus inhibit binding of the Grb-2 adapter to phosphorylated EGF receptor tyrosine kinase,"
March 1999
"Expression of Grb7 growth factor receptor signaling protein in kidney development and in adult kidney," co-author with Leavey, S.F., Arend, L.J., Dressler, G.R., Briggs, J.P. and Margolis, B.L., Am J Physiol., 275(5 Pt 2), November 1998, pp F770-6
November 1998
"IL-1 beta-converting enzyme (ICE) is present and functional in human alveolar macrophages: macrophage IL-1 beta release limitation is ICE independent,"
December 15, 1997
"Skeletal changes in multiparous, nulliparous and ovariectomized mice fed either a nutrient-sufficient or -deficient diet containing cadmium,"
April 30, 1997
"The combination of endotoxin and dexamethasone induces type II interleukin 1 receptor (IL-1r II) in monocytes: a comparison to interleukin 1 beta (IL-1 beta) and interleukin 1 receptor antagonist (IL-1ra),"
November 1996
Representative Matters
Authored Patents
  • U.S. 7,456,015: Tetracycline-Regulated Adeno-Associated Viral (AAV) Vectors for Gene Delivery to the Nervous System
  • E.P. 1,799,826 B1: siRNA-Mediated Silencing of a-Synuclein

Authored Published Patent Applications

  • U.S. 2006/0118189: Flow Variation Valve Assembly
  • U.S. 2007/0172462: siRNA-Mediated Gene Silencing of Synuclein
  • U.S. 2007/0178071: Stem-Cell, Precursor Cell, or Target Cell-Based Treatment of Multiorgan Failure and Renal Dysfunction
  • U.S. 2008/0027413: Blood Products from Mesenchymal Stem Cells
  • U.S. 2008/0051721: Loop Tip Wire Guide
  • U.S. 2008/0241112: Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media
  • U.S. 2008/0306465: Adjustable Length Catheter
Press Releases & Events
October 24, 2018
Brinks' Gary Ropski Named #1 Leading IP Lawyer in Illinois; Laura Beth Miller Named to Top 100 Leading Women Business Lawyers

CHICAGO—Brinks shareholder Gary M. Ropski has been named the #1 Leading Intellectual Property Lawyer in Illinois and  Laura Beth Miller has been recognized among the Top...

June 06, 2017
Legal 500 Recognizes Brinks Gilson & Lione as Top U.S. Patent Prosecution Firm for Ninth Consecutive Year

CHICAGO—Intellectual property law firm Brinks Gilson & Lione has been recognized for the ninth year in a row as a top U.S. firm for patent prosecution, including for re-examination and post-grant proceedings, by The Legal 500 United States 2017...

October 23, 2014
Brinks' Gary Ropski Named #1 Leading IP Lawyer in Illinois; 59 Brinks Attorneys Named Leading Lawyers for 2014-2015
CHICAGO—Gary M. Ropski, a shareholder at intellectual property law firm Brinks Gilson & Lione and the firm's past president, has been named the #1 Leading Intellectual Property Lawyer in Illinois by Leading Lawyers, and fifty-nine ...
Honors
  • Recommended Lawyer, Legal 500, 2017
  • Leading Intellectual Property Lawyer, Leading Lawyers Network, 2012-2016
Affiliations
  • American Bar Association
  • Illinois Biotechnology Industry Organization (iBIO)
Please read our privacy statement. Click here